Lewes, DE -- (SBWIRE) -- 05/25/2018 -- Radiation Injury - Pipeline Review, H1 2018, provides an overview of the Radiation Injury (Toxicology) pipeline landscape.

Radiation injury is damage to tissues caused by exposure to ionizing radiation. Symptoms depend on whether radiation exposure involves the whole body or is limited to a small portion of the body. At high doses, whole-body exposure causes acute radiation illness, and partial-body exposure causes local radiation injury.

Report Highlights
Radiation Injury - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Radiation Injury (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Injury (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 7, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Radiation Injury (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Injury (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Radiation Injury (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Radiation Injury (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Radiation Injury (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Injury (Toxicology)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Radiation Injury (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Radiation Injury (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 46 pages "Radiation Injury - Pipeline Review, H1 2018" report covers Introduction, Report Coverage, Radiation Injury - Overview, Radiation Injury - Therapeutics Development, Radiation Injury - Therapeutics Assessment, Radiation Injury - Companies Involved in Therapeutics Development, Radiation Injury - Drug Profiles, Radiation Injury - Dormant Projects, Appendix. This report Covered Companies - FirstString Research Inc, PharmaIN Corp, Synedgen Inc, Tonix Pharmaceuticals Holding Corp, Windtree Therapeutics Inc.

Please visit this link for more details: http://mrr.cm/UuM

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline Review, H1 2018 - Visit at - http://mrr.cm/UuY

Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2018 - Visit at - http://mrr.cm/Uug

About Market Research Reports, Inc.
Market Research Reports® Inc. is world's largest store offering quality market research , SWOT analysis, competitive intelligence and industry reports. We help Fortune 500 to Start-Ups with the latest market research reports on global & regional markets which comprise key industries, leading market players, new products and latest industry analysis & trends.

Press Contact:
Mr. Sudeep Chakravarty
Director - Operations
Market Research Reports, Inc.
USA: +1-302-703-9904

Contact us for your market research requirements: https://www.marketresearchreports.com/contact